Kornimate/medical-research-clean huggingface dataset:
subcutaneous (sc) darbepoetin alfa in subjects with symptomatic congestive heart failure (chf) & anemia

Conditions: Congestive Heart Failure; Anemia

Summary: the purpose of this study is to evaluate whether weight-based or fixed starting doses result in comparable hemoglobin increases and treatment effects in patients with heart failure and anemia.


Eligibility criteria:
inclusion criteria: - symptomatic chf for at least 3 months - reduced left ventricular ejection fraction - stable heart failure medication - hemoglobin concentration between 9.0 and 12.5 g/dl exclusion criteria: - hypertension - unstable angina pectoris or recent myocardial infarction - likely to receive cardiac transplant - major organ transplant (e.g., lung, liver, heart) or in renal replacement therapy (e.g., dialysis) - recent or current treatment for malignancy - systemic hematologic disease - anemia due to acute or chronic bleeding - recent epogen® or darbepoetin alfa therapy - recent blood transfusion

Keywords: symptomatic congestive heart failure chf anaemia anemia
blood pressure and central haemodynamics in healthy adults stratified by mthfr genotype

Conditions: Blood Pressure

Summary: approximately 12% of the world's population have a have a common c677t polymorphism in the gene encoding the folate metabolising enzyme, methylenetetrahydrofolate reductase (mthfr). homozygosity for the polymorphism (tt genotype) appears to result in an increased requirement for the b-vitamins folic acid and riboflavin and more importantly results in an increased risk of developing high blood pressure (bp). previous work from our centre has demonstrated significantly higher bp in those with the tt genotype. this work has been conducted in cohorts with premature cardiovascular disease (cvd) and hypertension without overt cvd, but the effect in younger, healthier individuals is unexplored. to date our studies have also focused on bp as the primary outcome, but newer markers of vascular health including central pressure and hemodynamics have emerged as superior prognostic indicators of cvd. the effect of the tt genotype on these measures is thus an important area for investigation and may help us understand the mechanism linking the genotype with bp, which is currently unknown. as adults with the tt genotype appear to have increased requirements for riboflavin and folic acid, and bp in tt adults appears to be riboflavin dependent, the influence of these vitamins on central measures is an area for consideration. study design this is an observational study investigating the blood pressure profiles of healthy adults aged 18-65 years, stratified by mthfr genotype. apparently healthy adults will be recruited from workplaces and the general community across northern ireland and screened for the polymorphism via buccal swab. those with the tt genotype and a similar number of non-tt (i.e. cc/ct) genotype individuals will be contacted and asked to come to attend a one-off appointment. brachial bp will be assessed by an electronic bp monitor, central bp and central haemodynamics (augmentation index, augmentation pressure and pulse wave velocity) will be assessed by sphygmocor xcel. in addition, anthropometric measurements, health and lifestyle information and a blood sample will be obtained. data will be statistically analysed using spss software to if determine differences between gentoype groups exist.


Eligibility criteria:
inclusion criteria: * pre-screened for mthfr 677tt genotype * aged at least 18 years old exclusion criteria: * younger than 18 years * pregnant

Keywords: blood pressure mthfr methylenetetrahydrofolate reductase central hemodynamics riboflavin folic acid folate polymorphism
efficacy of pregabalin versus combined pregabalin and milnacipran in fibromyalgia.

Conditions: Fibromyalgia, Primary

Summary: diagnosis of fibromyalgia is complex and treatment options are limited. pharmacological management of fibromyalgia is mainly centered on the central nervous system. in particular there is robust evidence for the use of tricyclic antidepressants (e.g., amitriptyline), anti-convulsants such as gabapentin or pregabalin and agents from the serotonin norepinephrine reuptake inhibitor (snri) family such as milnacipran. aim of the work: to compare the efficacy of pregabalin agent (averopreg) alone versus combined pregabalin and serotonin norepinephrine reuptake inhibitor (milnacipran) in the management of fibromyalgia.

subjects: the study will include 50 patients diagnosed as having fibromyalgia according to the acr 2010 fibromyalgia diagnostic criteria. methods: patients will be classified into two groups: 1) group 1: patients will receive pregabalin as a monotherapy and the doses will be administered according to the treatment recommendations for fibromyalgia in the package insert, starting by 50mg twice daily increasing to 100 mg twice daily within 1 week based on efficacy and tolerability. 7) group 2: patients will receive combined pregabalin and milnacipran and the doses will be administered according to the treatment recommendations for fibromyalgia in the package insert, starting by 50mg twice daily increasing to 100 mg twice daily within 1 week for the pregabalin and starting by 12.5 mg increasing gradually to reach 100 mg daily of milnacipran based on efficacy and tolerability.

Eligibility criteria:
inclusion criteria: * female patients * diagnosed as fibromyalgia according to the 2016 revision to the 2010/2011 fibromyalgia diagnostic criteria exclusion criteria: * patients with major medical disorders or uncontrolled medical conditions * patients with recent myocardial infarction or stroke, * patients with active liver disease, * patients with renal impairment (creatinine clearance \< 60 ml/min), * patients with documented autoimmune disease, * patients with severe chronic obstructive pulmonary disease, * patients with unstable diabetes, * pregnancy or breastfeeding patients * patients with exposed to any investigational drug within the past 6 months
oxaliplatin and gemcitabine followed by radiation therapy in the management of mixed mullerian tumors of the uterus

Conditions: Mixed Mullerian Tumors of the Uterus

Summary: the purpose of this research study is to determine the feasibility and safety of giving the combination of oxaliplatin and gemcitabine followed by radiation therapy and to learn whether or not this drug combined with radiation therapy works in treating women with mullerian tumors of the uterus.

objectives: primary to determine the feasibility of dual modality therapy described as cytotoxic therapy followed by radiation therapy for the management of malignant mixed mullerian tumors (mmmts). secondary \* to describe the response rate by response evaluation criteria in solid tumors statistical design: this study used a two-stage design to evaluate feasibility of oxaliplatin and gemcitabine prior to radiation therapy defined as completing 3 cycles of chemotherapy. the null and alternative therapy completion rates were 25% and 50%. if 3 or more participants enrolled in the stage one cohort (n=9 participants) complete therapy than accrual would proceed to stage two (n=15 participants). if therapy was completed by at least 10 participants in the final set of 24 evaluable participants then this regimen would be deemed worthy of further study. this design had 80% power given one-sided type i error of 5% with the probability of stopping early 0.60.

Eligibility criteria:
inclusion criteria: * surgically staged and histologically confirmed diagnosis of mmmt * 18 years of age or older * ecog performance score of 0-2 * adequate bone marrow function * adequate renal function * adequate hepatic function * patients must be recovered from both the acute and late effects of any prior surgery exclusion criteria: * patients with an active infection * patients with cns metastases * history of prior malignancy within the past 5 years except curatively treated basal cell carcinoma of the skin, or cervical intraepithelial neoplasia * known hypersensitivity to any of the components of oxaliplatin or gemcitabine * prior radiation to the pelvis * patients who are receiving concurrent investigational therapy or who have received investigational therapy within 30 days * peripheral neuropathy greater or equal to grade 2 * stage iv visceral disease (lung and liver metastases at presentation) * any other medical condition, including mental illness or substance abuse, deemed by the investigator to be likely to interfere with a patient's ability to sign informed consent * known hiv or hepatitis b or c (active, previously treated or both) * pregnant or breast feeding

Keywords: oxaliplatin gemcitabine mmmt
medical students and risk of covid-19 infection

Conditions: Covid19

Summary: this study aims to estimate the prevalence of infected medical students with covid-19 in the university of jordan and to compare number of cases between students in clinical and basic years. in addition, this can provide insight into the awareness of infection control practices among students. furthermore, to examine if hospital rotations increased risk of infection between clinical year medical students.


Eligibility criteria:
inclusion criteria: all medical students - exclusion criteria: * none
diagnostic performance of hybrid pet/mri in the staging of endometrial carcinoma

Conditions: Endometrial Carcinoma

Summary: endometrial carcinoma (ec) is one of the most common gynecologic malignancy in china. ec is staged surgically according to the international federation of gynecology and obstetrics (figo) system, including depth of myometrial invasion, cervical invasion, and the presence of lymph node metastases. the benefit of lymph node resection on the prognosis of low-risk ec patients is not definite. an accurate staging method preoperative is needed.the purpose of this study is to evaluate the effect of simultaneous hybrid pet/mri in ec preoperative staging.

the treatment of ec is mainly surgery, mostly comprehensive staging surgery (complete hysterectomy, bilateral adnexectomy, pelvic and para-aortic lymph node resection). lymph node metastasis rate in the early low-risk ec patients (histologically graded g1 and g2, myometrium invasion depth \<50%, primary tumor diameter \<2 cm) is low (\<4%). lymph node resection has no clear benefit on the prognosis of low-risk ec patients, but will bring greater trauma to the patients. accurate preoperative assessment of ec staging plays a decisive role in the individualized surgical range for ec patients. preoperative imaging can assist in optimal treatment planning. through ultrasound, mri, pet we always cannot accurately measure the depth of muscle infiltration, lymph node metastasis and extra-uterine lesions. the simultaneous hybrid pet/mri technology combines the characteristics of mri in high-resolution imaging of soft tissue and the advantages of pet in strong ability to identify tumor metastases, so it may be capable for more accurate staging.

Eligibility criteria:
inclusion criteria: * ec suspicious patients consent to diagnostic curettage * patients who pass standard clinical pet/mri screening procedures * undergoing surgical staging and/or debulking at xuanwu hospital, beijing exclusion criteria: * allergy to (18)f-fluoro-d-glucose * contraindication to mri scanning * pregnant or breast feeding patients * participation in any other clinical trial which may interfere with this study

Keywords: hybrid pet/mri
infectious pseudochromdrosis caused by bacillus cereus

Conditions: Infectious Disease; Bacterial Overgrowth; Pigment Deposition

Summary: twelve patients with blue sweat (infectious pseudochromhidrosis) caused by bacillus cereus.

case series/observational study. twelve patients with blue sweat (infectious pseudochromhidrosis) caused by bacillus cereus. demography, clinical presentation, diagnosis, treatments, microbiology and causality.

Eligibility criteria:
inclusion criteria: * infectious pseudochromhidrosis caused by bacillus cereus exclusion criteria: * other types of blue chromhidrosis

Keywords: infectious pseudochromhidrosis chromhidrosis sweat bacillus cereus
compliance and persistence with osteoporosis treatment and attitude towards future therapy among post-menopausal israeli women during drug treatment or drug holiday

Conditions: Osteoporosis

Summary: the purpose of the study is to provide information about the rate of response and persistence to drug therapies for osteoporosis. another issue examined in this study refers to the preferences and concerns about future treatments in patients during "drug holiday".


Eligibility criteria:
inclusion criteria: * postmenopausal women * diagnosis of osteoporosis in the medical record * at least one prescription drug to treat osteoporosis in the last 5 years * insured by "clalit" health services * hebrew-speaking capability and readiness to answer a questionnaire exclusion criteria: * premenopausal women * no diagnosis of osteoporosis in the medical record * no treatment for osteoporosis in the last 5 years * women who do not speak hebrew or are unable to answer a questionnaire

Keywords: osteoporosis postmenopausal patient compliance compliance diphosphonates bisphosphonates
antineoplaston therapy in treating patients with colon cancer

Conditions: Stage IV Colon Cancer; Recurrent Colon Cancer; Adenocarcinoma of the Colon

Summary: rationale: antineoplastons are naturally occurring substances that may also be made in the laboratory. antineoplastons may inhibit the growth of cancer cells. purpose: this phase ii trial is studying how well antineoplaston therapy works in treating patients with colon cancer.

objectives: * determine the antitumor activity of antineoplastons a10 and as2-1 in patients with adenocarcinoma of the colon by determining the proportion of patients who experience an objective tumor response. * evaluate the adverse effects of and tolerance to this regimen in these patients. outline: this is an open-label study. patients receive gradually escalating doses of oral antineoplaston a10 and oral antineoplaston as2-1 6-7 times a day. if the patient has not achieved a partial or complete response after 3-4 months of treatment, the investigator may discontinue treatment. patients with stable disease may continue to receive treatment until disease progression or unacceptable toxicity is observed. tumors are measured every 4 months during the first 2 years, then every 6 months during years 3 and 4, and yearly during years 5 and 6. projected accrual: a total of 20-40 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically confirmed adenocarcinoma of the colon that is unlikely to respond to existing therapy and for which no curative therapy exists * measurable disease by mri or ct scan * metastatic or unresectable disease patient characteristics: age: * 18 and over performance status: * karnofsky 60-100% life expectancy: * at least 2 months hematopoietic: * wbc at least 2,000/mm\^3 * platelet count at least 50,000/mm\^3 hepatic: * bilirubin no greater than 2.5 mg/dl * sgot/sgpt no greater than 5 times upper limit of normal * no hepatic failure renal: * creatinine no greater than 2.5 mg/dl * no renal failure cardiovascular: * no chronic heart failure * no uncontrolled hypertension pulmonary: * no serious lung disease, such as chronic obstructive pulmonary disease other: * not pregnant or nursing * fertile patients must use effective contraception during and for 4 weeks after study participation * no active infection * no serious malabsorption syndromes * no other serious concurrent disease prior concurrent therapy: biologic therapy: * at least 4 weeks since prior immunotherapy and recovered chemotherapy: * at least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered endocrine therapy: * concurrent corticosteroids allowed radiotherapy: * at least 8 weeks since prior radiotherapy and recovered (patients with multiple tumors may be admitted earlier) surgery: * no prior extensive stomach or intestinal surgery other: * prior cytodifferentiating agent allowed * no prior antineoplaston therapy * no other concurrent anticancer therapy
comparison of visual acuity performed in office versus in residence

Conditions: Refractive Errors

Summary: gocheck has developed and deployed a home-based visual acuity test that may be used in-office or in residence. the test methodology utilizes modified ats and etdrs protocols with sloan optotypes, crowding bars and sophisticated algorithms. the objective of this study is to determine if the results of the gocheck visual acuity test performed in an office setting correlate to the same testing when implemented in the residence

to address the increasing needs for remote patient assessment, gocheck has developed and deployed a home-based visual acuity test that may be used in-office or in residence, to meet the changing needs of providers visit time allocation, as well as presenting a standardized form of visual acuity centered around clinically-validated approaches. the test methodology utilizes modified etdrs design features with hotv or sloan optotypes (based on age), crowding bars, and displays 3 optotypes at a time (arranged vertically) to accommodate smaller screen sizes, but still significantly shortens testing time as opposed to displaying only a single optotype at a time. the application may be used to screen children old enough to comprehend the test, typically around age 4 through adulthood, during their primary care, or school-based visits, and now, in the home. the purpose of home vision testing is to provide actionable insights into the status of an individual's vision without the need for an in-office visit. the testing results will be able to used by the physician to help determine if additional interventions are necessary. the objective of this study is to determine if the results of the gocheck visual acuity test performed in an office setting correlate to the same testing when implemented in the residence.

Eligibility criteria:
inclusion criteria: 1. ages four (4) to twenty(20) years, inclusive 2. corrected visual acuity range of 20/16 to 20/100 3. manifest or cycloplegic refraction within prior six (6) months 4. ability to comprehend and complete the va test with age appropriate optotypes exclusion criteria: 1. no access to smartphone 2. inability to read, write, and/or understand english 3. inability to provide written informed consent or have consent conferred on patient's behalf 4. subjects from populations otherwise deemed ineligible/unable to provide informed consent and/or participate in studies (detention, correction, rehabilitation, psychiatric residents, etc.) 5. current pregnancy 6. any ocular pathology defect(s) except amblyopia, strabismus or refractive error or history of nystagmus.
epidemiological study on asymptomatic infections and mild illness with covid-19 in shanghai

Conditions: COVID-19

Summary: this study is to clarify the epidemiological characteristics of omicron variant infected persons in shanghai, such as distribution characteristics, host and clinical characteristics, disease outcome and risk factors. especially asymptomatic infections.


Eligibility criteria:
inclusion criteria: * sars-cov-2 rna positive. * asymptomatic or mild clinical manifestation. * informed consent signed. exclusion criteria: * informed consent rejected.
sensori-motor and perceptual functions of the ppc.

Conditions: Healthy Volunteers; Optic Ataxia

Summary: to produce hand's movement directed towards a target, the investigator must combine several sensory information, such as vision or proprioception. the posterior parietal cortex (ppc) is a region of the cortex involved in this multisensory integration. a lesion of the ppc cause a visuo-motor trouble called optic ataxia but these patients also have perceptual troubles. the aim of the study is to understand the different functions of the ppc and especially how the processes of spatial coding of the sensory information influences perception and motor planning. in this study, the investigator want to explore the sensory motor and the perceptual performance of patients with optic ataxia compared with healthy subjects, using 6 behavioral tests. objectify the consequences of ppc impairment (visual-motor and perceptual consequences) on patients' quality of life and autonomy.


Eligibility criteria:
inclusion criteria: all patients and healthy subjects: * male and female, age from 18 to 75 years included * normal vision or corrected vision * covered by social security * signed written informed consent patients: * neurological injury in posterior parietal cortex supported by a cerebral mri * present optic ataxia symptoms healthy subjects * no known neurological injury exclusion criteria: - unable to comply with the tasks (neurological, psychiatric, sensory or motor troubles)

Keywords: optic ataxia posterior parietal cortex functions multisensory integration
magnetic resonance imaging of patients with normal tension glaucoma

Conditions: Normal Tension Glaucoma

Summary: the purpose of this study is to study the occurrence rate of masses such as brain tumors in patients with newly diagnosed normal tension glaucoma.


Eligibility criteria:
inclusion criteria: * lack of understanding of the study * unable or unwilling to undergo mri

Keywords: glaucoma normal tensions glaucoma neuroradiology tumor mri magnetic resonance imaging compressive lesion
comparison of the efficacy of ultrasound-guided corticosteroid injection and paraffin therapy in carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: the aim of this study is to compare the efficacy of paraffin therapy, a physical therapy modality, and ultrasound-guided corticosteroid injection in the treatment of carpal tunnel syndrome, the most common entrapment neuropathy. by doing so, the study will evaluate the effectiveness and feasibility of these two alternative, low-side-effect treatments for managing this frequently encountered condition.

a total of 46 patients, aged 18-65, diagnosed with mild to moderate carpal tunnel syndrome based on electrophysiological studies, will be included in the study.pain levels will be assessed using the visual analog scale (vas), and functional impairment will be measured with the boston carpal tunnel syndrome questionnaire (bctq). electrophysiological evaluations will be performed by a neurology specialist at the 1st and 3rd month follow-ups outside of working hours and without being billed to the social security institution (sgk). vas, bctq scores, and electrophysiological parameters will be evaluated at baseline, and at the 4th and 12th-week follow-ups post-treatment. electrophysiological measurements will include median nerve distal motor latency (mmndl), median nerve distal sensory latency (mnsdl), sensory nerve conduction velocity (sncv), compound muscle action potential (cmap), and sensory nerve action potential (snap) amplitudes.

Eligibility criteria:
inclusion criteria: * patients aged 18-65. * diagnosed with mild to moderate carpal tunnel syndrome based on electrophysiological studies. * received either ultrasound-guided corticosteroid injection or paraffin therapy. * symptoms persisting for at least 3 months. exclusion criteria: * diagnosis of other conditions causing neuropathic symptoms (e.g., polyneuropathy, brachial plexopathy, thoracic outlet syndrome). * history of previous injection or surgery for carpal tunnel syndrome.